High expression of miR-210 predicts poor survival in patients with breast cancer: A meta-analysis

MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations

“…Concerning the importance of histological variant in ACC clinical outcome, we have confirmed the results of a retrospective survival analysis provided by Wong et al [26], in which was shown a better prognosis for malignant adrenocortical neoplasm showing predominant oncocytic features in comparison with those of classical type. The prognostic value of miR-210 has already been demonstrated in breast [33], pancreatic [34], head and neck carcinomas [35], pediatric osteosarcoma [36], and glioblastoma [37].…”

Original article Differential expression of microRNA-210 in gliomas of variable cell origin and correlation between increased expression levels and disease progression in astrocytic tumours

“…The expression of miR-210 has been shown to be correlated with a poor outcome in a variety of solid tumours, such as breast cancer [12], head and neck cancer [8], renal cancer [19], paediatric osteosarcoma [2] and acute ischemic stroke [43]. Meta-analysis has found that a high expression of miR-210 was an independent factor indicating a poor prognosis in 511 cases of breast cancer [12].…”

“…Meta-analysis has found that a high expression of miR-210 was an independent factor indicating a poor prognosis in 511 cases of breast cancer [12]. MiR-210 up-regulation showed a strong correlation with tumour aggressiveness in paediatric osteosarcoma, with a significant reduction in both overall survival and progression-free survival [2].…”

“…It has been demonstrated that miR-210 plays an important role in regulation of cell growth, angiogenesis, invasion and apoptosis in different human tumour models [5,11]. MiR-210 expression is frequently up-regulated in a variety of solid tumours, including breast cancer [12], non-small cell lung cancer [29], head and neck cancer [8], pancreatic cancer [4], oral tumours [31], hepatocellular cancer (HCC) [42], adrenocortical carcinoma (ACC) [23], glioblastoma [26], colon cancer [24], ovarian cancer [9], malignant melanoma [22] and renal cell cancer [27]. The expression of miR-210 is found to be down-regulated in human esophageal squamous cell carcinoma (ESCC) tissues and derived cell lines [34].…”

Hypoxia in breast cancer

“…Hong et al concluded that high expression of miR-210 might predict poor survival in patients with breast cancer [12]. Camps et al found that higher expression levels of miR-210 were correlated with shorter disease-free and overall survival in breast cancer [13].…”